FDA Delays Approval For Ultragenyx’s Gene Therapy, But Not A Dealbreaker, Says Analyst

All NewsJuly 14, 2025

Ultragenyx’s UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.

Latest Ratings for RARE

DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022JP MorganUpgradesNeutralOverweight Feb 2022Morgan StanleyMaintainsOverweight

View More Analyst Ratings for RARE

View the Latest Analyst Ratings

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent